Named in 2 fund letters, by Bireme Capital and Spheria Asset Management.
SEC CIK 0001682852 · Biological Products, (No Diagnostic Substances) · Incorporated in Delaware
| 3Q26 FV Letter: Going AI-Native | Bireme Capital argues that AI agents now let its two-person firm work like a full research team for under $1,000 a month, that AI will help new entrants displace incumbents, and that AI's profits will flow mostly to users, so it shorts AI suppliers while buying cheap Japanese compounders such as Kaga Electronics, M-Up and Noritsu Koki at 8 to 13 times earnings. | Bireme Capital | Bireme Capital | Q3 2026 |
| Spheria Global Smaller Companies Fund Report August 2026 | Spheria argues that SharkNinja and Paycom, which both raised full-year guidance for a second quarter running, rose on results already in their numbers, unlike the AI infrastructure trade, and it holds Paycom at 17 times FY27 EV/EBIT for its 50%+ return on invested capital. | Spheria Asset Management | Spheria Asset Management | Q3 2026 |
The shares surged +177% in a single session after Moderna and partner Merck announced their personalised messenger RNA cancer vaccine met its endpoints in a Phase 3 melanoma trial, the first such vaccine to succeed at this stage of testing.Show in the letter ›
Spheria Global Smaller Companies Fund Report August 2026 · Spheria Asset Management · page 2 · Q3 2026
Jorge Condenamed it in 5 interviews“Moderna CEO Stéphane Bancel on the Next Era of mRNA” (Raising Health, 2026)
Vineeta Agarwalanamed it in 2 interviews“What’s hype/ what’s real beyond the headlines (and beyond the press release), when it comes to the announcement last week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19 -- and relatedly, the most recent news around Moderna's vaccine candidate?” — What to Know about Those Vaccines (The a16z Show, 2020)
Brad Stonenamed it in 1 interview“(32:40) Matt and Ron discuss Moderna's prospects, Pepsi's new logo, and share two stocks on their radar: ERP Properties and Wesco International.” — Surprisingly Strong Q1, Stocks To Watch, Bezos' Next Move (Motley Fool Hidden Gems Investing, 2023)| Moderna CEO Stéphane Bancel on the Next Era of mRNA | Jorge Conde | Raising Health | 2026-09-02 | a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases. Resources: Follow Stéphane Bancel on LinkedIn: https://www.linkedin.com/in/st%C3%A9phane-bancel-8185251/ Follow Jorge Conde on X: https://x.com/JorgeCondeBio Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| Surprisingly Strong Q1, Stocks To Watch, Bezos' Next Move | Brad Stone | Motley Fool Hidden Gems Investing | 2023-03-31 | 40 min | The Nasdaq rose 17% in the 1st quarter, but we're not popping champagne just yet. (0:21) Ron Gross and Matt Argersinger discuss: - New inflation data and real estate concerns in Silicon Valley - Why they're watching company margins and guidance updates over the next few weeks - Disney shutting down its metaverse division - Lululemon's (unsurprising) write-down of Mirror - The latest from Walgreens, RH, and McCormick (19:11) Brad Stone, head of Bloomberg's global tech coverage, weighs in on the state of affairs at Amazon, whether Jeff Bezos will return as CEO, and what to watch in the growing industry of AI and ChatGPT. (32:40) Matt and Ron discuss Moderna's prospects, Pepsi's new logo, and share two stocks on their radar: ERP Properties and Wesco International. To get your copy of our free report "Top Stocks For Rising Interest Rates" just go to fool.com/interest. Stocks discussed: DIS, META, LULU, WBA, RH, MKC, AMZN, GOOG, MRNA, PEP, EPR, WCC Host: Chris Hill Guests: Ron Gross, Matt Argersinger, Brad Stone Engineer: Dan Boyd Learn more about your ad choices. Visit megaphone.fm/adchoices |
| A Shot to Save The World — Gregory Zuckerman [S.5, Ep.6] | Gregory Zuckerman | Real Talk: The Charles Mizrahi Show | 2021-11-30 | 56 min | Subscribe to Charles' Alpha Investor newsletter today: https://pro.banyanhill.com/m/2054150 A group of unlikely researchers saved millions of lives when they developed the COVID-19 vaccine. But their stories were lost in the shuffle … until now. Award-winning journalist Gregory Zuckerman shares their full journey in his latest book. And in this episode, he discusses the science behind the vaccines, the companies that raced to develop them, and the future of the virus with host Charles Mizrahi. Topics Discussed: An Introduction to Gregory Zuckerman (00:00:00) The Innovative Disruptor (00:06:47) Re-writing the Script (00:11:21) Unlikely Characters Save the Day (00:17:16) Moderna Rises to the Challenge (00:28:54) Skeptics & Politics (00:35:28) A Sea Change in Development (00:44:05) The Future of COVID-19 (00:50:14) Guest Bio: Gregory Zuckerman is an award-winning journalist and bestselling author. In addition to being a special writer for The Wall Street Journal and a three-time winner of the Gerald Loeb Award, Zuckerman has written several books that span business and science. His latest book (below) describes the race to develop a vaccine that would save the world. |
| U.S. Surgeon General Dr. Vivek Murthy & SPANX Founder Sara Blakely | Ann Chung | Squawk Pod | 2021-10-22 | SPANX has accepted its first outside investor in its 21-year history: Blackstone. Sara Blakely, founder of the billion-dollar shapewear company , shares stories of her start, decades ago, Blackstone’s all-female deal team, and disrupting retail. Blackstone’s Ann Chung discusses striking the deal and betting on shapewear amid a pandemic. Pfizer has revealed that in its clinical trial, its Covid-19 vaccine proved over 90% effective in kids aged 5-11 . Plus, the CDC has approved Moderna and Johnson & Johnson Covid-19 booster vaccines for the elderly, immunocompromised, and adults over 18. U.S. Surgeon General Dr. Vivek Murthy discusses both announcements, and what Americans can expect as we head into the colder months. WeWork survived its first day of trading, but Snap had a rough day on the market. In this episode: Dr. Vivek Murthy, @Surgeon_General Sara Blakely, @SPANX Becky Quick, @BeckyQuick Andrew Ross Sorkin, @andrewrsorkin Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. | |
| mRNA for Flu Vaccine? AI Protein-Folding Goes Open Source | Jorge Conde | 16 Minutes News by a16z | 2021-08-02 | In today’s episode we have two short segments, both on bioscience topics: [0:00] Moderna has started clinical trials for a flu vaccine, called mRNA-1010, that is based on the same mRNA technology that Moderna and Pfizer used for their COVID vaccines, and that several other companies including Sanofi and Glaxo all are actively working on for the influenza use case. Our experts are general partners Vineeta Agarwala and Jorge Conde of the a16z bio team, who have joined us on many of our vaccine-related episodes, which you can find at a16z.com/vaccines. They discuss what comes next for the clinical trials of this mRNA-based flu vaccines, why companies aren't planning to use the faster and more-targeted mRNA technology for COVID's Delta variant, and how mRNA vaccines will change not only our approach to flu shots but to other respiratory viruses. [9:53] Google’s DeepMind AlphaFold, in partnership with the European Molecular Biology Laboratory, is publicly sharing its entire protein structure database -- with predicted protein structure models for ~20,000 proteins expressed by the human genome -- meaning that all its data will be freely and openly available to the scientific community. (We previously discussed DeepMind's AlphaFold protein-folding AI on this show in episode #48.) General partner Vijay Pande of the a16z bio team helps us answer the question: Why does it matter that a huge database of very accurate predicted protein structures is now freely available? | |
| What to Know about Those Vaccines | Jorge Conde, Vineeta Agarwala | The a16z Show | 2020-11-20 | A vaccine for COVID seems to be (almost) here… or is it? What’s hype/ what’s real beyond the headlines (and beyond the press release), when it comes to the announcement last week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19 -- and relatedly, the most recent news around Moderna's vaccine candidate? Of course, this was just the first interim efficacy analysis — so how close or far are we? What’s the significance of the readout and case numbers? How do we put all this in context of all the other (458!) programs in development? And how much should/ shouldn’t we read into the news, given the buzzy excitement and penchant for evaluating "science via press release"? a16z bio general partners Vineeta Agarwala and Jorge Conde recently broke it all down in conversation with Sonal Chokshi on our show 16 Minutes: the math, the science, and the practical considerations — from “vaccine efficacy” vs. efficiency, from cold chains to distribution, from patients to the system… as well as why mRNA matters in the present future of vaccines. | |
| Covid Vaccine! Beyond Science via Press Release | Jorge Conde, Vineeta Agarwala | 16 Minutes News by a16z | 2020-11-14 | A vaccine for COVID seems to be (almost) here... or is it? What's hype/ what's real beyond the headlines (and beyond the press release), when it comes to the announcement earlier this week from Pfizer and BioNTech that their vaccine candidate was found to be more than 90% effective in preventing COVID-19? Of course, this was just the first interim efficacy analysis -- so how close or far are we? What's the significance of the readout and case numbers? How do we put this (and related approaches, like Moderna's) in context of all the other (458!) programs in development? And how much should/ shouldn't we read into this news? After all, it's "difficult to evaluate science via press release", as some say. So in this episode of 16 Minutes with a16z bio general partners Vineeta Agarwala and Jorge Conde in conversation with Sonal Chokshi, we break it all down: the math, the science, and the practical considerations -- from "vaccine efficacy" vs. efficiency, from cold chains to distribution, from patients to the system... as well as from the past, to present future of, vaccines. references and readings cited in this episode: BioCentury.com/coronavirus , COVID-19 therapies and vaccines: Clinical; COVID-19 therapies and vaccines: Preclinical; COVID-19 Clinical Trial Dashboard, November 2020 " Vaccine Efficacy 101: A biostatistician's primer ", Natalie E. Dean, Twitter, September 2020 " Understanding COVID-19 vaccine efficacy ", Marc Lipsitch and Natalie E. | |
| Inside Moderna’s Biggest mRNA Test Since COVID | Jorge Conde | The a16z Show |
RA Shot to Save The World — Gregory Zuckerman [S.5, Ep.6]Real Talk: The Charles Mizrahi Show · 2021-11-30
TInside Moderna’s Biggest mRNA Test Since COVIDThe a16z Show